{# ── Non-reliance notice. Reaching the live report with one of these means it did not meet the blocking bar (the 4.02 names this period outside the Item 4.02 body) or the viewer is staff. Either way the reader must not take the figures at face value. ── #}

Get notified when TLRY files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: TLRY Tilray Brands, Inc. 8-K

Tilray reports record $915M revenue, guides FY2027 adjusted EBITDA to $68M-$75M

Filed July 28, 2026 · Period ending July 28, 2026 · ~1 min read

Key Changes

  • high

    FY2026 revenue rose 11% to $915.5M with adjusted EBITDA of $61.1M (up 11% YoY); company reduced net debt to $0.7M and ended year with ~$235M in cash and marketable securities.

    Exhibit 99.1 view on EDGAR →
  • high

    Guides FY2027 adjusted EBITDA to $68M-$75M (double-digit growth) and expects over $1B in annual revenue.

    Exhibit 99.1 view on EDGAR →
  • high

    International medical cannabis revenue grew 34% in FY2026; CC Pharma pharmaceutical distribution gross profit increased 57% in Q4, demonstrating operating leverage.

    Exhibit 99.1 view on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (IMMR 10-K) is open in full — no account needed.

Partner

Trade TLRY commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov Press release (Ex 99.1) on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jul 29, 2026 · How we verify